Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Silver Trust (SLV) vs Viatris Inc (VTRS) Price & Performance

iShares Silver TrustTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares Silver Trust vs Viatris Inc — how do they compare? iShares Silver Trust trades at $54.78 (market cap $29.02B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares Silver Trust is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Viatris Inc for 57 Days on average.

SLVVTRS
Market Cap
$29.02B$20.03B
Volume
16,510,33414,109,977
52-Week High
$105.57$18.27
52-Week Low
$42.40$9.74
Typical Hold Time
89 Days57 Days
Sector
—Health
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Silver Trust

SLV (iShares Silver Trust) trades at $53.45, down 0.69% with a bearish technical signal. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Assets surged to $13.41B while liabilities remain negligible at $5.98K. Technical indicators show oversold conditions with RSI at 26.02, though moving averages signal continued bearish pressure.

The outlook remains challenged by Federal Reserve policy uncertainty and rising Treasury yields pressuring precious metals. While oversold conditions may provide short-term bounce potential, the fundamental case lacks revenue generation. Investors face headwinds from dollar strength and hawkish Fed expectations, requiring careful risk management in this volatile sector.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SLV
40% Buy60% Sell
Avg holding period · 89 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About iShares Silver Trust

The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.

Read more on SLV →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →